The interplay of circadian rhythms and cancer pain: a narrative review

Cancer-associated pain affects the majority of patients with advanced disease, involves complex nociceptive, neuropathic, and psychosocial mechanisms, and remains inadequately controlled despite available pharmacological options. Circadian rhythms regulate sleep-wake patterns, hormone secretion, immune function, and nociceptive signaling. Their disruption, common in cancer patients due to disease burden, treatment side effects, and psychological distress, may influence both pain perception and analgesic response. This narrative review examines the interplay between chronobiology and cancer-associated pain, evaluating the biological plausibility and clinical readiness of chronotherapy, the role of non-pharmacological circadian-supportive interventions, and the exploratory contribution of medical cannabis within this framework.

Circadian patterns in cancer pain and breakthrough cancer pain are inconsistent at the population level, with discrepancies between clinical reports of late-morning peaks and experimental evidence of nocturnal pain sensitivity, suggesting that observed patterns are largely driven by pharmacokinetic, activity-related, and tumor-specific factors. Opioid pharmacokinetics and pharmacodynamics are influenced by circadian variation, and aligning dosing with individual pain and metabolic patterns may theoretically enhance analgesic efficacy, though prospective evidence remains limited. Opioid therapy itself disrupts circadian organization, reinforcing the value of strategies that simultaneously time drug administration and support circadian stability. Non-pharmacological interventions including sleep hygiene, light therapy, structured exercise, and psychological approaches carry established safety profiles and consistent benefits on quality of life, though their direct analgesic contribution within a chronotherapy framework remains to be established. The endocannabinoid system exhibits circadian rhythmicity, but robust trial data supporting medical cannabis for cancer pain and sleep regulation are absent, and current guidelines maintain a cautious stance. The identification of objective circadian biomarkers is a critical prerequisite before chronotherapy can be evaluated in phase III trials.

Circadian biology offers a biologically plausible but insufficiently validated framework for optimizing cancer pain management. Clinicians can already incorporate sleep hygiene measures, morning light exposure, and structured physical activity into existing cancer pain management plans while awaiting higher-level evidence. Future research must prioritize biomarker validation, large-scale RCTs of timed opioid administration, and implementation science to translate chronotherapy from hypothesis to guideline-level practice.